Table 2.
Periodontal characteristics of patients with RA before and after medication with inhibitors of IL‐6 receptor and tumor necrosis factor.
| Characteristics | Group | Baseline | 3 months | 6 months |
|---|---|---|---|---|
| GI | TCZ (n = 20) | 1.01 ± 0.12 | 0.85 ± 0.17 * | 0.81 ± 0.18 * |
| TNFI (n = 40) | 0.93 ± 0.21 | 0.85 ± 0.22 * | 0.81 ± 0.22 * | |
| % sites with plaque | TCZ (n = 20) | 37.4 ± 25.8 | 36.7 ± 23.9 | 33.2 ± 22.1 |
| TNFI (n = 40) | 35.6 ± 18.7 | 30.7 ± 18.0 | 28.7 ± 19.2 | |
| % sites with BOP | TCZ (n = 20) | 8.2 ± 10.2 | 2.1 ± 3.8 * | 1.9 ± 3.8 * |
| TNFI (n = 40) | 10.4 ± 11.3 | 7.1 ± 7.9 * | 6.8 ± 7.6 * | |
| PD (mm) | TCZ (n = 20) | 2.57 ± 0.32 | 2.48 ± 0.22 * | 2.45 ± 0.24 * |
| TNFI (n = 40) | 2.65 ± 0.34 | 2.57 ± 0.34 * | 2.51 ± 0.33 * | |
| % sites with PD ≥ 4 mm | TCZ (n = 20) | 9.9 ± 14.6 | 4.3 ± 4.5 | 4.2 ± 4.6 |
| TNFI (n = 40) | 11.6 ± 12.1 | 10.9 ± 14.8 | 11.5 ± 17.6 | |
| CAL (mm) | TCZ (n = 20) | 2.63 ± 0.31 | 2.58 ± 0.30 * | 2.55 ± 0.31 * |
| TNFI (n = 40) | 2.72 ± 0.35 | 2.73 ± 0.45 | 2.70 ± 0.44 | |
| % sites with CAL ≥ 4 mm | TCZ (n = 20) | 11.5 ± 14.5 | 8.8 ± 10.4 | 8.6 ± 10.4 |
| TNFI (n = 40) | 13.1 ± 13.0 | 15.0 ± 18.0 | 16.0 ± 20.2 |
RA, rheumatoid arthritis; GI, gingival index; BOP, bleeding on probing; PD, probing depth; CAL, clinical attachment level; TCZ, tocilizumab; TNFI, tumor necrosis factor inhibitor; n, number.
Values represent the mean ± standard deviation, and the bold values show the statistical significance.
*
Significantly different from the baseline, as assessed by Friedman and Wilcoxon signed rank tests (p < 0.017).